First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback